Market anxiety subsided significantly as oil prices and interest rates stabilized on expectations of de-escalation between the U.S. and Iran. In addition, investment enthusiasm revived as major technology firms unveiled new artificial intelligence technologies and continued investments.
Geopolitical tensions eased following discussions on de-escalating the U.S.-Iran conflict and proposals to reopen the Strait of Hormuz
Inflation concerns eased as international crude oil prices fell sharply on expectations of reduced geopolitical risk in the Middle East
U.S. Treasury yields, which had surged intra-day, pulled back to stabilize amid falling oil prices and hopes for progress in Middle East talks
AI tech stocks gained strength on Microsoft's unveiling of new AI agents and news of large-scale cloud contracts
Optimistic outlooks continued, including Meta's price target hike and bullish broker ratings on key tech stocks
Despite the surge in oil prices, concerns over an actual economic recession have eased, driving investment sentiment into commodities and energy infrastructure assets. Furthermore, rising power demand for AI coupled with the restructuring of global supply chains is strengthening buying pressure in the solar and advanced technology components sectors.
Despite recession fears driven by surging oil prices, real oil prices and leading indicators suggest a low probability of immediate stagflation, heightening interest in commodity sector rotation.
Expectations surrounding the implementation of Section 232 of the U.S. Trade Expansion Act are expanding momentum for major domestic solar companies that have secured non-Chinese solar supply chains.
LNG midstream infrastructure companies are expected to benefit from the U.S.-led restructuring of LNG supply chains following the Middle East crisis, combined with surging power demand from AI data centers.
The expanded field deployment of global humanoid robots and moves to establish non-Chinese supply chains are driving order expectations for domestic precision reducer and actuator component manufacturers.
Amid accelerating AI drug discovery collaboration between global big pharma and big tech, domestic biotech companies equipped with proprietary experimental data and platforms are expected to secure technology transfer deals.
